Clinical Trials Browser

Phase 2 × Hemangiosarcoma × trebananib × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01623869 2015-10-19

Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery

Phase 2 Completed

16 enrolled 6 charts

Hemangiosarcoma, Sarcoma